For API manufacturing, formulation, biosimilar, distribution and diagnostics targets — a structured feasibility framework that answers the market, molecule, customer and business-plan questions in sequence, typically within 12 weeks.
Global and segment-level market size (synthetic, biologic, HPAPI, sterile) and the growth drivers behind it — volume, price, or new product introductions.
Scoring candidate molecules against demand, price trend, competitive intensity and fit with plant capability, including competitor pricing strategy.
How generic majors, CDMOs/CMOs and formulation companies actually buy — procurement cycles, price sensitivity, and vendor-selection criteria (credit terms, supply performance, quality, DMF/CEP/GMP documentation).
Revenue by product, margin after raw-material and packaging benchmarks, operating costs, capex and working capital, feeding an NPV/IRR view with scenario analysis.
Every feasibility study includes direct interviews with competitors and customers — not just published data — because pricing strategy, vendor-selection reality and procurement behaviour rarely show up in a database.
Diligence support for pharma and healthcare M&A transactions, alongside the core feasibility work.
Compliance review for manufacturing plants as part of technical due diligence.
Assessing exposure and opportunity ahead of upcoming patent expiries, feeding into both diligence and competitive intelligence work.
Export-import considerations relevant to manufacturing and distribution feasibility.